Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2018

Open Access 01-12-2018 | Commentary

Cardiovascular medicine in China: what can we do to achieve the Healthy China 2030 plan?

Authors: Yihua Bei, Tingting Yang, Junjie Xiao

Published in: BMC Medicine | Issue 1/2018

Login to get access

Abstract

Cardiovascular diseases (CVDs) represent the leading cause of death in China. The Chinese government approved the Healthy China 2030 plan (jiànkāng zhōngguó 2030), emphasizing the strategic role of health in China’s development. As morbidity and mortality from CVDs are constantly increasing in China, the prevention and treatment of CVDs are vital to achieve this plan. Following the major principles of health priority, science and technology innovation, scientific development, and balanced medical resource allocation outlined in the Healthy China 2030 plan, this Commentary briefly introduces the current status of CVDs in China and marks the important events undertaken to achieve this plan.
Literature
1.
Chen W, Gao R, Liu L, Zhu M, Wang W, Wang Y, Wu Z, Li H, Gu D, Yang Y, et al. Summary of the report on cardiovascular diseases in China (2017). Chin Circ J. 2018;33(01):1–8.
2.
National Center for Cardiovascular Diseases, China. Report on Cardiovascular Diseases in China 2017. Beijing: Encyclopedia of China Publishing House; 2018.
3.
4.
Cai Y, Zhu X, Wu X. Overweight, obesity, and screen-time viewing among Chinese school-aged children: national prevalence estimates from the 2016 physical activity and fitness in China—the youth study. J Sport Health Sci. 2017;6(4):404–9.CrossRefPubMedPubMedCentral
5.
van Donkelaar A, Martin RV, Brauer M, Kahn R, Levy R, Verduzco C, Villeneuve PJ. Global estimates of ambient fine particulate matter concentrations from satellite-based aerosol optical depth: development and application. Environ Health Perspect. 2010;118(6):847–55.CrossRefPubMedPubMedCentral
6.
Xie W, Li G, Zhao D, Xie X, Wei Z, Wang W, Wang M, Li G, Liu W, Sun J, et al. Relationship between fine particulate air pollution and ischaemic heart disease morbidity and mortality. Heart. 2015;101(4):257–63.CrossRefPubMed
7.
Xie X, Wang Y, Yang Y, Xu J, Zhang Y, Tang W, Guo T, Wang Q, Shen H, Zhang Y, et al. Long-term effects of ambient particulate matter (with an aerodynamic diameter ≤2.5 μm) on hypertension and blood pressure and attributable risk among reproductive-age adults in China. J Am Heart Assoc. 2018;7(9):e008553.
8.
9.
Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313(13):1336–46.CrossRefPubMed
10.
Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in “real-world” practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv. 2009;2(4):303–9.CrossRefPubMed
11.
Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, Li X, Zhao X, Wang H, Zhao X, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer Sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv. 2016;9(2):e003145.CrossRefPubMed
12.
Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157(4):733–9.CrossRefPubMed
13.
Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol. 2015;66(21):2298–309.CrossRefPubMed
14.
Pu J, Ding S, Ge H, Han Y, Guo J, Lin R, Su X, Zhang H, Chen L, He B, et al. Efficacy and safety of a Pharmaco-invasive strategy with half-dose Alteplase versus primary angioplasty in ST-segment-elevation myocardial infarction: EARLY-MYO trial (early routine catheterization after Alteplase fibrinolysis versus primary PCI in acute ST-segment-elevation myocardial infarction). Circulation. 2017;136(16):1462–73.CrossRefPubMed
15.
Zhang Y, Zhang J, Butler J, Yang X, Xie P, Guo D, Wei T, Yu J, Wu Z, Gao Y, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry. J Card Fail. 2017;23(12):868–75.CrossRefPubMed
16.
Ren J, Xu Q, Chen X, Li W, Guo K, Zhao Y, Wang Q, Zhang Z, Peng H, Li YG. Superaligned carbon nanotubes guide oriented cell growth and promote electrophysiological homogeneity for synthetic cardiac tissues. Adv Mater. 2017;29(44):1702713.
17.
Bi Y, Jiang Y, He J, Xu Y, Wang L, Xu M, Zhang M, Li Y, Wang T, Dai M, et al. Status of cardiovascular health in Chinese adults. J Am Coll Cardiol. 2015;65(10):1013–25.CrossRefPubMed
18.
Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Committee of Chinese Association of Rehabilitation Medicine, Committee of Cardio-Cerebral-Vascular Diseases of Gerontological Society of China. Chinese experts consensus on cardiac rehabilitation/secondary prevention for coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41(4):267–75.
Metadata
Title
Cardiovascular medicine in China: what can we do to achieve the Healthy China 2030 plan?
Authors
Yihua Bei
Tingting Yang
Junjie Xiao
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2018
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-018-1133-4

Other articles of this Issue 1/2018

BMC Medicine 1/2018 Go to the issue

Debate

Hospital Mortality – a neglected but rich source of information supporting the transition to higher quality health systems in low and middle income countries

Research article

The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review

Commentary

Guideline developers are not the only experts: Utilising the FRAM method in sepsis pathways

Research article

Fitness to practise sanctions in UK doctors are predicted by poor performance at MRCGP and MRCP(UK) assessments: data linkage study

Research article

Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study

Commentary

Informing real-world practice with real-world evidence: the value of PRECIS-2